Moreover, co-administration of HDACIs and anti-CTLA4 (cytotoxic T-lymphocyte antigen 4) antibodies seems to act synergistically for the therapeutic effect, enhancing T-cell infiltration within the tumor and the anti-tumor immune response [44]. Here, CTLA4 is linked to neoplasm.